Log In
Print
BCIQ
Print
Print this Print this
 

RXDX-101

  Manage Alerts
Collapse Summary General Information
Company Nerviano Medical Sciences s.r.l.
DescriptionOral c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1), neurotrophic tyrosine kinase receptor 1 (NTRK1; TrkA), TrkB, TrkC and anaplastic lymphoma kinase (ALK) inhibitor
Molecular Target c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1) ; Neurotrophic tyrosine kinase receptor 1 (NTRK1) (TrkA)
Mechanism of ActionKinase inhibitor; Anaplastic lymphoma kinase (Ki-1) (ALK) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I/II
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation

Partner

Ignyta Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today